AstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as it continues to slim down and invest in its pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback